Merck (MRK) Stock Gains Today on Positive Phase III Melanoma Treatment Study Results

March 24, 2015 6:01 PM

10 0

Merck (MRK) Stock Gains Today on Positive Phase III Melanoma Treatment Study Results

NEW YORK (TheStreet) -- Merck(MRK - Get Report) shares are up 0.83% to $59.22 in market trading on Tuesday after the biopharmaceutical company reported that it is discontinuing the phase III trials of its advanced melanoma treatment Keytruda after an independent committee concluded that the drug met its two primary endpoints of progression-free survival and overall survival.

The drug treatment was successful in increasing the survival rate of patients with advanced stages of melanoma who had not yet been treated for the disease. Keytruda had already received prior approval as a treatment for advanced stages of melanoma in patients who were no longer responsive to other ...

Read more

To category page

Loading...